Edition:
United Kingdom

NanoVibronix Inc (NAOV.OQ)

NAOV.OQ on NASDAQ Stock Exchange Capital Market

4.60USD
15 Feb 2018
Change (% chg)

-- (--)
Prev Close
$4.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$4.90
52-wk Low
$3.68

Chart for

About

NanoVibronix, Inc. is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy. The Company's products include PainShield, WoundShield and UroShield. Its products under development include Renooskin and Endotrachshield. The Company's principal research and... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $19.27
Shares Outstanding(Mil.): 2.63
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.19 16.64
EPS (TTM): -- -- --
ROI: -- 13.90 10.66
ROE: -- 16.72 14.30

BRIEF-Nanovibronix Inc - Signed Morulaa Healthtech As Its Regulatory And Marketing Partner In India

* NANOVIBRONIX INC - SIGNED MORULAA HEALTHTECH AS ITS REGULATORY AND MARKETING PARTNER IN INDIA Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

20 Dec 2017

BRIEF-NanoVibronix Names IMS Ultrasound (UK) Ltd As Its Exclusive UK Distributor For Uroshield

* NANOVIBRONIX ANNOUNCES IMS ULTRASOUND (UK) LTD AS ITS EXCLUSIVE UK DISTRIBUTOR FOR UROSHIELD(TM) FOLLOWING SUCCESSFUL INTERIM TRIAL RESULTS

14 Dec 2017

BRIEF-Nanovibronix Announces Exclusive U.K. Distributor For Painshield

* NANOVIBRONIX ANNOUNCES EXCLUSIVE UK DISTRIBUTOR FOR PAINSHIELD(TM) PROVIDING PATIENTS AN ALTERNATIVE TO OPIOIDS AND SURGERY

05 Dec 2017

BRIEF-Nanovibronix ‍Expects To Complete Trial For Use Of Painshield In Patients With Trigeminal Neuralgia In Q1 Of 2018​

* NANOVIBRONIX REPORTS SUCCESSFUL INTERIM TRIAL RESULTS FOR USE OF PAINSHIELD(TM) IN PATIENTS WITH TRIGEMINAL NEURALGIA; REPRESENTS POTENTIAL ALTERNATIVE TO OPIOID AND SURGICAL INTERVENTIONS

29 Nov 2017

Earnings vs. Estimates